ACTI Active Biotech AB

Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Tuesday, May 19, 2020, at 5 p.m. in the Company’s offices, Scheelevägen 22 in Lund, Sweden.

INFORMATION RELATING TO THE CORONA VIRUS

As a result of the Corona virus, Active Biotech kindly asks the shareholders not to participate in this years’ Annual General Meeting in person. Instead, Active Biotech encourages shareholders to carefully consider the possibility of participating in the meeting by way of proxy or advance voting (see below). Any questions to be raised by shareholders at the Meeting can be sent to the Company by e-mail to in advance of the Meeting. Written answers to the questions raised will be posted on the Company’s website after the Meeting.

ENTITLEMENT TO PARTICIPATE

Shareholders who wish to participate in the Meeting must (i) be recorded in the register of shareholders maintained by Euroclear Sweden AB on Wednesday, May 13, 2020, and (ii) notify the Company of their intention to participate in the Meeting not later than on Wednesday, May 13, 2020.

     Shareholders who have trustee-registered their shares must register the shares in their own name to be entitled to participate in the Meeting. Such registration, which may be temporary, must be completed on Wednesday, May 13, 2020. Accordingly, shareholders must inform the trustee of this request in ample time prior to this date.

There are 145,236,480 shares and votes in Active Biotech. The Company holds no treasury shares.

NOTICE OF PARTICIPATION

Notice of participation in the Meeting can be made in writing to Active Biotech AB (publ), Attn: Susanne Jönsson, P.O. Box 724, SE-220 07 Lund, Sweden, by telephone +46 (0)46-19 20 00 or by e-mail to . The notice shall include name, personal/corporate identity number, number of shares held, daytime telephone number and, if applicable, the number of advisors (not more than two) that will accompany the shareholder at the Meeting.

Shareholders represented by proxy shall issue a dated and signed power of attorney for the proxy. If the power of attorney is issued on behalf of a legal entity, a certified copy of a registration certificate or corresponding document indicating the authorized signatories of the legal entity shall be appended. The original power of attorney and, where applicable, the certificate should be submitted to the Company at the address indicated above well in advance of the Meeting. Proxy forms are provided at the Company’s website, , and sent to shareholders that so request.

ADVANCE VOTING

The shareholders may exercise their voting rights at the Annual General Meeting by voting in advance. Active Biotech encourages all shareholders to use this opportunity in order to minimise the number of participants attending the Meeting in person and thus reduce the spread of the Corona virus.

A special form shall be used for advance voting. The form is available on Active Biotech’s website, . A shareholder exercising its voting right through advance voting do not need to notify the Company of its attendance to the Meeting. The advance voting form is considered as the notification of attendance to the Meeting.

The completed voting form must be submitted to Active Biotech so it is received no later than Wednesday, May 13, 2020. The completed and signed form shall be sent to the postal address or e-mail address stated under the section “Notice of participation” above. If the shareholder is a legal entity or is voting in advance by proxy, a certificate of incorporation or a corresponding document shall be enclosed to the form. The shareholder may not qualify the advance vote with special instructions or conditions. If so, the vote is invalid. Further instructions and conditions is included in the form for advance voting.

PROPOSED AGENDA

  1. Opening of the Meeting
  2. Election of Chairman of the Meeting
  3. Preparation and approval of the voting list
  4. Election of one or two persons to verify the minutes
  5. Approval of the agenda for the Meeting
  6. Determination of whether the Meeting has been duly convened
  7. Presentation of the Annual Report and the Auditors’ Report, and the Consolidated Accounts and the Auditors’ Report for the Group
  8. Resolution concerning the adoption of the Income Statement and the Balance Sheet, and the Consolidated Income Statement and the Consolidated Balance Sheet
  9. Resolution concerning the disposition of the Company’s results pursuant to the adopted Balance Sheet
  10. Resolution on discharge from liability of the members of the Board of Directors and the CEO
  11. Determination of the number of members and alternate members of the Board of Directors and the number of auditors and alternate auditors
  12. Determination of fees payable to the Board of Directors and auditor
  13. Election of the Board of Directors, Chairman of the Board and auditor

        a) re-election of Michael Shalmi,

        b) re-election of Uli Hacksell,

        c) re-election of Peter Thelin,

        d) new election of Axel Glasmacher,

        e) new election of Aleksandar Danilovski,

        f) new election of Elaine Sullivan,

        g) re-election of Michael Shalmi as Chairman of the Board, and

        h) re-election of KPMG AB as auditor of the Company.

  1. Resolution concerning Election Committee
  2. The Board of Director’s proposal regarding guidelines for remuneration of senior executives
  3. The Board of Director’s proposal regarding amendment of the Articles of Association
  4. The Board of Director’s proposal regarding implementation of a long-term performance-based incentive program for the Company’s employees
  5. MGA Holding AB’s proposal regarding implementation of a long-term performance-based incentive program for Board members
  6. The Board of Director’s proposal regarding share issue authorization
  7. Closing of the Meeting

For full notice of Active Biotech's Annual General Meeting on May 19, including proposed resolutions, see attached PDF or .

DOCUMENTATION, ETC.

The Annual Report and other supporting resolution documentation will be held available at the Company’s premises at Scheelevägen 22 in Lund, Sweden, and on the Company’s website, , not later than three weeks prior to the Meeting. The documents will be sent to shareholders who request a copy and specify their postal address. Shareholders are reminded of their right to request information under Chapter 7, Section 32 of the Swedish Companies Act.

For information about the processing of your personal data, please refer to . Active Biotech’s corporate registration number is 556223-9227 and its registered office is in Lund, Sweden.

Lund, April 2020

The Board of Directors of Active Biotech AB (publ)

Attachment

EN
20/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Active Biotech AB

 PRESS RELEASE

Successful completion of the first stage of the phase IIa clinical tri...

Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage Lund, June 1, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab estafenatox (NAP, naptumomab), in combination with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with chemotherapy and checkpoint inhibitors (CPIs). In th...

 PRESS RELEASE

Det första steget av den kliniska fas IIa studien med naptumomab i kom...

Det första steget av den kliniska fas IIa studien med naptumomab i kombination med docetaxel har framgångsrikt slutförts och rekryteringen till andra steget av studien pågår Lund, 1 juni 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) och dess partner NeoTX tillkännager idag det framgångsrika slutförandet av det första steget av en adaptiv (Simon 2 stage) klinisk fas IIa studie med naptumomab estafenatox (NAP, naptumomab), i kombination med docetaxel i patienter med avancerad icke-småcellig lungcancer (NSCLC) som tidigare har behandlats med kemoterapi och checkpointhämmare  (CPI). I studien ...

 PRESS RELEASE

Annual General Meeting of Active Biotech AB

Annual General Meeting of Active Biotech AB The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, without any physical attendance. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2021, and that the Company’s accumulated loss shall be carried forward. The members of the Board and the CEO were discharged from liability with respect to their manag...

 PRESS RELEASE

Årsstämma i Active Biotech AB

Årsstämma i Active Biotech AB Active Biotechs årsstämma hölls den 19 maj 2022. Mot bakgrund av coronaviruset genomfördes årsstämman med poströstning, utan fysiskt deltagande. Följande huvudsakliga beslut fattades. I enlighet med styrelsens förslag beslutades att ingen utdelning skulle lämnas för räkenskapsåret 2021 och att bolagets ansamlade förlust skulle balanseras i ny räkning. Styrelsens ledamöter och verkställande direktören beviljades ansvarsfrihet för 2021 års förvaltning. I enlighet med valberedningens förslag omvaldes styrelseledamöterna Michael Shalmi, Uli Hack...

 PRESS RELEASE

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis   Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. “The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for Active Biotech”, said Helén Tuvesson, CEO Active Biotech. “It opens an important regulatory pathway and provides us with the potential to rapidly advance the development of  tasquinimod in thi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch